Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors

AIM: To study the clinical benefits of concurrent metformin and immune checkpoint inhibitors (ICIs) in non-small-cell lung cancer patients. MATERIALS & METHODS: This is a retrospective review of 50 non-small-cell lung cancer patients receiving ICIs with metformin (cohort A) or without metformin...

Descripción completa

Detalles Bibliográficos
Autores principales: Afzal, Muhammad Z, Dragnev, Konstantin, Sarwar, Tayyaba, Shirai, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802712/
https://www.ncbi.nlm.nih.gov/pubmed/31645894
http://dx.doi.org/10.2217/lmt-2018-0016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6802712/
https://www.ncbi.nlm.nih.gov/pubmed/31645894
http://dx.doi.org/10.2217/lmt-2018-0016

Ejemplares similares